All In Biotech

Drug Trial Radar · NCT05451199

A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

154

Planned (sponsor's estimate)

Start

Jul 29, 2022

Primary completion

Oct 30, 2023

Study completion Dec 31, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis

Conditions

  • Psoriasis

Interventions

  • ICP-488Drug

    ICP-488 will be administered as tablet

  • PlaceboDrug

    Matching placebo will be administered as tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events during treatment, and withdrawal from treatment due to adverse eventsTime frame: Single ascending dose: 1day;Multiple ascending dose: 28 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Meidcal University

    Hefei, Anhui, China · Not yet recruiting

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Nanyang First People's Hospital

    Nanyang, Henan, China · Not yet recruiting

  • Shiyan Renmin Hospital

    Shiyan, Hubei, China · Recruiting

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of medical Sciences, Peking Union Medical College

    Nanjing, Jiangsu, China · Recruiting

  • Yanbian University Hospital

    Yanji, Jilin, China · Not yet recruiting

  • Hangzhou First People's Hospital

    Hangzhou, Zheajing, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.